Evidence map›Paper›PMID 40161702›Full record

ArticlebioRxiv : the preprint server for biology2025

High-throughput neutralization measurements correlate strongly with evolutionary success of human influenza strains.

Caroline Kikawa, Andrea N Loes, John Huddleston, Marlin D Figgins, Philippa Steinberg, Tachianna Griffiths, Elizabeth M Drapeau, Heidi Peck, Ian G Barr, Janet A Englund and 3 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Caroline KikawaDivision of Basic Sciences and Computational Biology Program, Fred Hutch Cancer Center, Seattle, WA.ORCID 0000-0002-8654-5663
Andrea N LoesDivision of Basic Sciences and Computational Biology Program, Fred Hutch Cancer Center, Seattle, WA.ORCID 0000-0002-8659-0149
John HuddlestonVaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, WA.ORCID 0000-0002-4250-2063
Marlin D FigginsDivision of Basic Sciences and Computational Biology Program, Fred Hutch Cancer Center, Seattle, WA.ORCID 0000-0002-0686-0816
Philippa SteinbergVaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, WA.ORCID 0000-0002-2127-2692
Tachianna GriffithsDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Elizabeth M DrapeauDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-8243-6478
Heidi PeckWHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria 3000, Australia.
Ian G BarrWHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria 3000, Australia.
Janet A EnglundSeattle Children's Research Institute, Seattle, WA.ORCID 0000-0003-1134-4178
Scott E HensleyDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Trevor BedfordHoward Hughes Medical Institute, Seattle, WA.ORCID 0000-0002-4039-5794
Jesse D BloomDivision of Basic Sciences and Computational Biology Program, Fred Hutch Cancer Center, Seattle, WA.ORCID 0000-0003-1267-3408

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00015 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HENSLEY, SCOTT · 2021 to 2025
$50.7M
ChimeraX -- Next Generation Visualization and Analysis Software for Multiscale ModelingR01GM129325 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2018 to 2025
$5.2M
Forecasting influenza evolution on a heterogeneous immune landscapeR01AI165821 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Jesse D Bloom, JOHN HUDDLESTON · 2022 to 2026
$3.0M
Viral Pathogenesis Training ProgramT32AI083203 · NIAID · UNIVERSITY OF WASHINGTON · PI BLOOM, JESSE D, LAGUNOFF, MICHAEL · 2009 to 2023
$2.7M
High-Performance Compute Cluster for Comprehensive Cancer and Infectious Diseases ResearchS10OD028685 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRADLEY, PHILIP · 2020 to 2020
$2.0M
FHCRC High-Performance Computing ClusterS10OD020069 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KOOPERBERG, CHARLES L · 2015 to 2015
$600k
NCI NIH HHS P30 CA015704NIAID NIH HHS 75N93021C00015NIAID NIH HHS R01 AI165821NIAID NIH HHS T32 AI083203NIGMS NIH HHS R01 GM129325NIH HHS S10 OD020069NIH HHS S10 OD028685
6 · The paper itself

Abstract

Human influenza viruses rapidly acquire mutations in their hemagglutinin (HA) protein that erode neutralization by antibodies from prior exposures. Here, we use a sequencing-based assay to measure neutralization titers for 78 recent H3N2 HA strains against a large set of children and adult sera, measuring ~10,000 total titers. There is substantial person-to-person heterogeneity in the titers against different viral strains, both within and across age cohorts. The growth rates of H3N2 strains in the human population in 2023 are highly correlated with the fraction of sera with low titers against each strain. Notably, strain growth rates are less correlated with neutralization titers against pools of human sera, demonstrating the importance of population heterogeneity in shaping viral evolution. Overall, these results suggest that high-throughput neutralization measurements of human sera against many different viral strains can help explain the evolution of human influenza.

Identifiers

PMID40161702
PMCPMC11952370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.